EP300 and precursor B-cell acute lymphoblastic leukemia: To fully understand the oncogenic mechanism underlying EP300-ZNF384, we compared the expression profiles of EP300-ZNF384 fusion-positive B-ALL patients to negative patients using publicly available data from TARGET (n = 204).